Yazar "Bodur, Hatice" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Yayın
    Polypharmacy in the Elderly: A Multicenter Study
    (ELSEVIER SCIENCE INC, 2009) Kutsal, Yesim Gokce; Barak, Anil; Atalay, Ayce; Baydar, Terken; Kucukoglu, Selcuk; Tuncer, Tiraje; Hizmetli, Sami; Dursun, Nigar; Eyigor, Sibel; Saridogan, Merih; Bodur, Hatice; Canturk, Ferhan; Turhanoglu, Ayse; Arslan, Sule; Basaran, Aynur
    Objective: The aim of this study was to evaluate the polypharmacy issue and its correlations with socio-economic variables in Turkish elderly patients. Design: Cross-sectional Setting: Outpatient clinics of the medical schools, departments of physical medicine and rehabilitation from 12 provinces. Participants: A total of 1430 elderly in different geographical regions of Turkey during January 2007 to January 2008 were included. Measurements: Patients were interviewed using a questionnaire that included demographic characteristics, current medical diagnosis, and pharmaceuticals that are used by elderly. Demographical parameters were gender, age, marital status, number of children, level of education, province, and status of retirement. Results: The mean number of drugs was found to be higher in the females. There was a significant difference among age groups, marital status groups, and the number of children categories. The distribution of the number of drugs among education levels did not differ significantly, whereas the distribution of the number of drugs between the status of retirement and presence of chronic disease differed significantly. Conclusions: Polypharmacy is correlated with various factors including age, sex, marital status, number of children, status of retirement, and presence of chronic medical conditions but not educational status in our study group. (J Am Med Dir Assoc 2009; 10: 486-490)
  • Küçük Resim Yok
    Yayın
    Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR
    (TURKISH LEAGUE AGAINST RHEUMATISM, 2015) Ataman, Sebnem; Surmeli, Zuhre Sari; Sunar, Ismihan; Ozdemirel, Erhan; Akinci, Aysen; Bodur, Hatice; Akgul, Ozgur; Altan, Lale; Altay, Zuhal; Ayhan, Figen; Birtane, Murat; Soy Bugdayci, Derya; Capkin, Erhan; Cerrahoglu, Lale; Duruoz, Mehmet Tuncay; Gunaydin, Rezzan; Gunendi, Zafer; Gurer, Gulcan; Bal, Ajda; Kacar, Cahit; Kaptanoglu, Ece; Kaya, Taciser; Kocabas, Hilal; Kotevoglu, Nurdan; Nas, Kemal; Rezvani, Aylin; Sen, Nesrin; Sendur, Omer Faruk; Yalcin, Peyman
    Objectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey. Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected. Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same. Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.